Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy

References

• Sadozai H, Gruber T, Hunger RE, et al. Recent and future directions in immunotherapy of cutaneous melanoma. Front Immunol. 2017;8:1617.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600F) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study. Lancet Oncol. 2014 Mar;15(3):323–332.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open- label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovsky DL, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 1;386(9992):444–451.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Sep 23;363(13):1290.
   Web of Science ®Google Scholar
• Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007 Jul;12(7):873–883.
   PubMed Web of Science ®Google Scholar
• Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4-treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):375–384.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun;372(26):2521–2532.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–1356.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Kluger H, Sznol M, et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res. 2016 Jul;76(14 Suppl):abstr CT001.
   Google Scholar
• Danielli R, Fonsatti E, Calabrò L, et al. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann N Y Acad Sci. 2012;1270:8–12.
   PubMed Web of Science ®Google Scholar
• Garaci E, Mastino A, Pica F, et al. Combination treatment using thymosin alpha one and interferon after cyclophosphamide is able to cure lewis lung carcinoma in mice. Cancer Immunol Immunother. 1990;32(3):154–160.
   PubMed Web of Science ®Google Scholar
• Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994 Jun 1;57(5):701–705.
   PubMed Web of Science ®Google Scholar
• Giuliani C, Napolitano G, Mastino A, et al. Thymosin alpha 1 regulates MHC expression in FRTL-5 cells at trascriptional level. Eur JImmunol. 2000 Mar;30(3):778–786.
   PubMed Web of Science ®Google Scholar
• Sinibaldi Vallebona P, Pierimarchi P, Moroni G, et al. Thymalfasin up-regulates tumor antigen expression in colorectal cancer cells. Tumor Biol. 2002;23:45.
   Google Scholar
• Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010 Apr;28(10):1780–1787.
   PubMed Web of Science ®Google Scholar
• O’Day S, Weber J, Lebbe C, et al. Effect of Ipilimumab treatment on 18-months survival: update of patients (pts) with advanced melanoma treated with 10mg/Kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(15 suppl):9033.
   Google Scholar
• Altomonte M, Di Giacomo A, Queirolo P, et al. Clinical experience with ipilimumab 10 mg/Kg in patients with melanoma treated at Italian centres as part of a european expanded access programme. J Exp Clin Cancer Res. 2013 Oct 25;32:82.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/Kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014 May 7;12:116.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previiously untreated metastatic melanoma. N Engl J Med. 2011 June 30;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015 Jun 10;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/Kg within an expanded access programme. Cancer Immunol Immunother. 2013 Jun;62(6):1021–1028.
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015 Jun;112(12):1904–1910.
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Gandini S, Cocorocchio E, et al. Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. Oncotarget. 2017 Aug 1;8(45):79809–79815.
   PubMedGoogle Scholar
• Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/Kg versus ipilimumab 3mg/Kg in patients with unresectable or metastatic melanoma: a randomized, double blind, multicentre, phase 3 trial. Lancet Oncol. 2017 Apr;18(5):611–622.
   PubMed Web of Science ®Google Scholar